A. Blauvelt, “Durability of DLQI Improvements Among Patients with Moderate to Severe Plaque Psoriasis Treated with Certolizumab Pegol: Three-Year Results from Two Phase 3 Trials (CIMPASI-1 and CIMPASI-2)”, J of Skin, vol. 4, no. 6, p. s80, Oct. 2020.